Michael Pursley

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial

Michael E. Nassif, Sheryl L. Windsor, Barry A. Borlaug et al. · Nature Medicine · 2021 · 572 citations · Full text

Hypertension, Heart Failure, Cardiomyopathy +14

Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction

Michael E. Nassif, Sheryl L. Windsor, Fengming Tang et al. · Circulation · 2019 · 415 citations

Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial

Mikhail Kosiborod, Russell Esterline, Remo H.M. Furtado et al. · The Lancet Diabetes & Endocrinology · 2021 · 235 citations · Full text

Cardiovascular Disease, Cardiometabolic Risk, Cardiovascular Pharmacology +11

Efficient Concerted Integration by Recombinant Human Immunodeficiency Virus Type 1 Integrase without Cellular or Viral Cofactors

Sapna Sinha, Michael Pursley, Duane P. Grandgenett · Journal of Virology · 2002 · 73 citations · Full text

A 14,500 MW protein is coded by region E3 of group C human adenoviruses

Ann E. Tollefson, Péter Krajcsi, Michael Pursley et al. · Virology · 1990 · 54 citations

Virus Structure, Region E3, Molecular Biology +8